Covered recipient · General Payments record
PATRICIA A SCHECHTER
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$5,624.61
- Reported across 343 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $500.63 | 34 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $264.24 | 22 |
| GlaxoSmithKline, LLC. | $40.14 | 2 |
| ALK-Abello, Inc | $31.56 | 2 |
| GENZYME CORPORATION | $26.13 | 1 |
| Lilly USA, LLC | $22.90 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $22.57 | 1 |
| IBSA Pharma Inc. | $21.34 | 1 |
| AIMMUNE THERAPEUTICS, INC. | $20.28 | 1 |
| Novo Nordisk AS | $18.71 | 1 |
| Amgen Inc. | $18.07 | 1 |
| PFIZER INC. | $14.69 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $6.64 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031748 | CMS |
| ABBVIE INC. | $20.60 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031750 | CMS |
| ABBVIE INC. | $19.94 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031752 | CMS |
| ABBVIE INC. | $4.02 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031754 | CMS |
| ABBVIE INC. | $9.40 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031756 | CMS |
| ABBVIE INC. | $8.99 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031758 | CMS |
| ABBVIE INC. | $14.73 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031760 | CMS |
| ABBVIE INC. | $26.57 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031762 | CMS |
| ABBVIE INC. | $3.12 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031764 | CMS |
| ABBVIE INC. | $20.03 | 07/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031766 | CMS |
| ABBVIE INC. | $8.39 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031768 | CMS |
| ABBVIE INC. | $11.56 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031770 | CMS |
| ABBVIE INC. | $2.00 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031772 | CMS |
| ABBVIE INC. | $25.77 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031774 | CMS |
| ABBVIE INC. | $16.83 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031776 | CMS |
| ABBVIE INC. | $6.80 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031778 | CMS |
| ABBVIE INC. | $16.94 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031780 | CMS |
| ABBVIE INC. | $7.74 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031782 | CMS |
| ABBVIE INC. | $7.17 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031784 | CMS |
| ABBVIE INC. | $7.57 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031786 | CMS |
| ABBVIE INC. | $13.09 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031788 | CMS |
| ABBVIE INC. | $6.34 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106031790 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $20.28 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147017261 | CMS |
| ALK-Abello, Inc | $14.05 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1099895015 | CMS |
| ALK-Abello, Inc | $17.51 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1099895017 | CMS |
| Amgen Inc. | $18.07 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116093560 | CMS |
| GENZYME CORPORATION | $26.13 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139607606 | CMS |
| GlaxoSmithKline, LLC. | $19.28 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116474415 | CMS |
| GlaxoSmithKline, LLC. | $20.86 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115939620 | CMS |
| IBSA Pharma Inc. | $21.34 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142976230 | CMS |
| Lilly USA, LLC | $22.90 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135306537 | CMS |
| Novo Nordisk Inc | $18.71 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097360077 | CMS |
| PFIZER INC. | $14.69 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131154322 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $22.57 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137669356 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.